{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:31:07Z","timestamp":1791621067548,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA214641"],"award-info":[{"award-number":["CA214641"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["DE016572"],"award-info":[{"award-number":["DE016572"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 pandemic exerts a health care emergency around the world. The illness severity is heterogeneous. It is mostly unknown why some individuals who are positive for SARS-CoV-2 antibodies stay asymptomatic while others show moderate to severe disease symptoms. Reliable biomarkers for early detection of the disease are urgently needed to attenuate the virus\u2019s spread and help make early treatment decisions. Bioactive sphingolipids play a crucial role in the regulation of viral infections and pro-inflammatory responses involved in the severity of COVID-19. However, any roles of sphingolipids in COVID-19 development or detection remain unknown. In this study, lipidomics measurement of serum sphingolipids demonstrated that reduced sphingosine levels are highly associated with the development of symptomatic COVID-19 in the majority (99.24%) SARS-CoV-2-infected patients compared to asymptomatic counterparts. The majority of asymptomatic individuals (73%) exhibited increased acid ceramidase (AC) in their serum, measured by Western blotting, consistent with elevated sphingosine levels compared to SARS-CoV-2 antibody negative controls. AC protein was also reduced in almost all of the symptomatic patients\u2019 serum, linked to reduced sphingosine levels, measured in longitudinal acute or convalescent COVID-19 samples. Thus, reduced sphingosine levels provide a sensitive and selective serologic biomarker for the early identification of asymptomatic versus symptomatic COVID-19 patients.<\/jats:p>","DOI":"10.1038\/s41598-021-93857-7","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T10:02:44Z","timestamp":1625824964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Alhaji H.","family":"Janneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Faisal","family":"Kassir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor J.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramita","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish N.","family":"Nadig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikhar","family":"Mehrotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besim","family":"Ogretmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"93857_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cancers12061581","volume":"12","author":"A Allegra","year":"2020","unstructured":"Allegra, A., Pioggia, G., Tonacci, A., Musolino, C. & Gangemi, S. Cancer and SARS-CoV-2 infection: Diagnostic and therapeutic challenges. Cancers 12, 1581 (2020).","journal-title":"Cancers"},{"key":"93857_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F. & Krammer, F. SARS-CoV-2 vaccines: Status report. Immunity 52, 583\u2013589 (2020).","journal-title":"Immunity"},{"key":"93857_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao, X. COVID-19: Immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269\u2013270 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"93857_CR4","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Investig."},{"key":"93857_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827. https:\/\/doi.org\/10.3389\/fimmu.2020.00827 (2020).","journal-title":"Front. Immunol."},{"key":"93857_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang, J., Jiang, M., Chen, X. & Montaner, L. J. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J. Leukoc. Biol. 108, 17\u201341. https:\/\/doi.org\/10.1002\/JLB.3COVR0520-272R (2020).","journal-title":"J. Leukoc. Biol."},{"key":"93857_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye, Q., Wang, B. & Mao, J. The pathogenesis and treatment of the \u2018Cytokine Storm\u2019 in COVID-19. J. Infect. 80, 607\u2013613 (2020).","journal-title":"J. Infect."},{"key":"93857_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cca.2020.06.017","volume":"509","author":"P Song","year":"2020","unstructured":"Song, P., Li, W., Xie, J., Hou, Y. & You, C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta 509, 280\u2013287 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"93857_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489-1501.e1415 (2020).","journal-title":"Cell"},{"key":"93857_CR10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Preliminary report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"93857_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s42399-021-00915-2","author":"V Hapshy","year":"2021","unstructured":"Hapshy, V. et al. COVID-19 and pregnancy: Risk, symptoms, diagnosis, and treatment. Compr. Clin. Med. https:\/\/doi.org\/10.1007\/s42399-021-00915-2 (2021).","journal-title":"Compr. Clin. Med."},{"key":"93857_CR12","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1002\/jmv.26816","volume":"93","author":"KK Sahu","year":"2021","unstructured":"Sahu, K. K., George, L., Jones, N. & Mangla, A. COVID-19 in patients with sickle cell disease: A single center experience from Ohio, United States. J. Med. Virol. 93, 2591\u20132594 (2021).","journal-title":"J. Med. Virol."},{"key":"93857_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.120.16472","volume":"77","author":"JP Sheppard","year":"2021","unstructured":"Sheppard, J. P. et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: An observational cohort study. Hypertension 77, 846\u2013855 (2021).","journal-title":"Hypertension"},{"key":"93857_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41569-020-0413-9","volume":"17","author":"M Nishiga","year":"2020","unstructured":"Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B. & Wu, J. C. COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives. Nat. Rev. Cardiol. 17, 543\u2013558 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"93857_CR15","first-page":"1603","volume":"325","author":"BM Kuehn","year":"2021","unstructured":"Kuehn, B. M. More severe obesity leads to more severe COVID-19 in study. JAMA 325, 1603\u20131603 (2021).","journal-title":"JAMA"},{"key":"93857_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki, R. et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149-168 e117. https:\/\/doi.org\/10.1016\/j.cell.2020.11.025 (2021).","journal-title":"Cell"},{"key":"93857_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","volume":"53","author":"N Mangalmurti","year":"2020","unstructured":"Mangalmurti, N. & Hunter, C. A. Cytokine storms: Understanding COVID-19. Immunity 53, 19\u201325 (2020).","journal-title":"Immunity"},{"key":"93857_CR18","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.immuni.2011.09.019","volume":"35","author":"P Muranski","year":"2011","unstructured":"Muranski, P. et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35, 972\u2013985 (2011).","journal-title":"Immunity"},{"key":"93857_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJ van der Windt","year":"2012","unstructured":"van der Windt, G. J. & Pearce, E. L. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol. Rev. 249, 27\u201342 (2012).","journal-title":"Immunol. Rev."},{"key":"93857_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/eji.201243008","volume":"43","author":"J Rolf","year":"2013","unstructured":"Rolf, J. et al. AMPK \u03b11: A glucose sensor that controls CD 8 T-cell memory. Eur. J. Immunol. 43, 889\u2013896 (2013).","journal-title":"Eur. J. Immunol."},{"key":"93857_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ni.2714","volume":"14","author":"AL Doedens","year":"2013","unstructured":"Doedens, A. L. et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nat. Immunol. 14, 1173 (2013).","journal-title":"Nat. Immunol."},{"key":"93857_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2012.01.015","volume":"36","author":"RR Rao","year":"2012","unstructured":"Rao, R. R., Li, Q., Gubbels Bupp, M. R. & Shrikant, P. A. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. Immunity 36, 374\u2013387. https:\/\/doi.org\/10.1016\/j.immuni.2012.01.015 (2012).","journal-title":"Immunity"},{"key":"93857_CR23","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1084\/jem.20130392","volume":"210","author":"R Hess Michelini","year":"2013","unstructured":"Hess Michelini, R., Doedens, A. L., Goldrath, A. W. & Hedrick, S. M. Differentiation of CD8 memory T cells depends on Foxo1. J. Exp. Med. 210, 1189\u20131200. https:\/\/doi.org\/10.1084\/jem.20130392 (2013).","journal-title":"J. Exp. Med."},{"key":"93857_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ni.3415","volume":"17","author":"C-H Chang","year":"2016","unstructured":"Chang, C.-H. & Pearce, E. L. Emerging concepts of T cell metabolism as a target of immunotherapy. Nat. Immunol. 17, 364\u2013368 (2016).","journal-title":"Nat. Immunol."},{"key":"93857_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck, M. D. et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166, 63\u201376 (2016).","journal-title":"Cell"},{"key":"93857_CR26","doi-asserted-by":"publisher","first-page":"104ra100","DOI":"10.1126\/scitranslmed.3002949","volume":"3","author":"I Kryczek","year":"2011","unstructured":"Kryczek, I. et al. Human TH17 cells are long-lived effector memory cells. Sci. Transl. Med. 3, 104ra100. https:\/\/doi.org\/10.1126\/scitranslmed.3002949 (2011).","journal-title":"Sci. Transl. Med."},{"key":"93857_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmet.2017.10.006","volume":"27","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee, S. et al. CD38-NAD(+)axis regulates immunotherapeutic anti-tumor T cell response. Cell Metab. 27, 85-100 e108. https:\/\/doi.org\/10.1016\/j.cmet.2017.10.006 (2018).","journal-title":"Cell Metab."},{"key":"93857_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer 18, 33\u201350. https:\/\/doi.org\/10.1038\/nrc.2017.96 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"93857_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar5551","author":"A Cartier","year":"2019","unstructured":"Cartier, A. & Hla, T. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science https:\/\/doi.org\/10.1126\/science.aar5551 (2019).","journal-title":"Science"},{"key":"93857_CR30","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3389\/fimmu.2019.01706","volume":"10","author":"A Weigert","year":"2019","unstructured":"Weigert, A., Olesch, C. & Brune, B. Sphingosine-1-phosphate and macrophage biology-how the sphinx tames the big eater. Front. Immunol. 10, 1706. https:\/\/doi.org\/10.3389\/fimmu.2019.01706 (2019).","journal-title":"Front. Immunol."},{"key":"93857_CR31","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1073\/pnas.1107024108","volume":"108","author":"KB Walsh","year":"2011","unstructured":"Walsh, K. B. et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Natl. Acad. Sci. U.S.A. 108, 12018\u201312023. https:\/\/doi.org\/10.1073\/pnas.1107024108 (2011).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"93857_CR32","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1038\/s41598-019-41760-7","volume":"9","author":"J Zhao","year":"2019","unstructured":"Zhao, J. et al. Combination of sphingosine-1-phosphate receptor 1 (S1PR1) agonist and antiviral drug: A potential therapy against pathogenic influenza virus. Sci. Rep. 9, 5272. https:\/\/doi.org\/10.1038\/s41598-019-41760-7 (2019).","journal-title":"Sci. Rep."},{"key":"93857_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","volume":"510","author":"M Maceyka","year":"2014","unstructured":"Maceyka, M. & Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 510, 58\u201367. https:\/\/doi.org\/10.1038\/nature13475 (2014).","journal-title":"Nature"},{"key":"93857_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102180","volume":"42","author":"C Foerch","year":"2020","unstructured":"Foerch, C., Friedauer, L., Bauer, B., Wolf, T. & Adam, E. H. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Mult. Scler. Relat. Disord. 42, 102180. https:\/\/doi.org\/10.1016\/j.msard.2020.102180 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"93857_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117011","volume":"416","author":"L Bollo","year":"2020","unstructured":"Bollo, L. et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. J. Neurol. Sci. 416, 117011. https:\/\/doi.org\/10.1016\/j.jns.2020.117011 (2020).","journal-title":"J. Neurol. Sci."},{"key":"93857_CR36","doi-asserted-by":"publisher","first-page":"15174","DOI":"10.1074\/jbc.RA120.015249","volume":"295","author":"MJ Edwards","year":"2020","unstructured":"Edwards, M. J. et al. Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. J. Biol. Chem. 295, 15174\u201315182. https:\/\/doi.org\/10.1074\/jbc.RA120.015249 (2020).","journal-title":"J. Biol. Chem."},{"key":"93857_CR37","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1172\/JCI64791","volume":"123","author":"JC Cheng","year":"2013","unstructured":"Cheng, J. C. et al. Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J. Clin. Investig. 123, 4344\u20134358. https:\/\/doi.org\/10.1172\/JCI64791 (2013).","journal-title":"J. Clin. Investig."},{"key":"93857_CR38","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1096\/fj.09-145508","volume":"24","author":"E Eliyahu","year":"2010","unstructured":"Eliyahu, E. et al. Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization. FASEB J. 24, 1229\u20131238. https:\/\/doi.org\/10.1096\/fj.09-145508 (2010).","journal-title":"FASEB J."},{"key":"93857_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ymgme.2008.08.003","volume":"95","author":"S Ramsubir","year":"2008","unstructured":"Ramsubir, S. et al. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Mol. Genet. Metab. 95, 133\u2013141 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"93857_CR40","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","volume":"11","author":"S De Biasi","year":"2020","unstructured":"De Biasi, S. et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat. Commun. 11, 3434. https:\/\/doi.org\/10.1038\/s41467-020-17292-4 (2020).","journal-title":"Nat. Commun."},{"key":"93857_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd2071","author":"D Weiskopf","year":"2020","unstructured":"Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abd2071 (2020).","journal-title":"Sci. Immunol."},{"key":"93857_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.molimm.2020.10.006","volume":"128","author":"JJ Guirao","year":"2020","unstructured":"Guirao, J. J., Cabrera, C. M., Jimenez, N., Rincon, L. & Urra, J. M. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Mol. Immunol. 128, 64\u201368. https:\/\/doi.org\/10.1016\/j.molimm.2020.10.006 (2020).","journal-title":"Mol. Immunol."},{"key":"93857_CR43","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","volume":"146","author":"A Copaescu","year":"2020","unstructured":"Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J. & Trubiano, J. A. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J. Allergy Clin. Immunol. 146, 518-534 e511. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.001 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"93857_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385. https:\/\/doi.org\/10.1038\/s41590-020-00808-x (2021).","journal-title":"Nat. Immunol."},{"key":"93857_CR45","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.toxrep.2020.06.003","volume":"7","author":"A Nasi","year":"2020","unstructured":"Nasi, A. et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. Toxicol. Rep. 7, 768\u2013771 (2020).","journal-title":"Toxicol. Rep."},{"key":"93857_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.arcmed.2020.04.019","volume":"51","author":"L Delgado-Roche","year":"2020","unstructured":"Delgado-Roche, L. & Mesta, F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch. Med. Res. 51, 384\u2013387 (2020).","journal-title":"Arch. Med. Res."},{"key":"93857_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/v13010090","volume":"13","author":"JE Tanner","year":"2021","unstructured":"Tanner, J. E. & Alfieri, C. The fatty acid lipid metabolism nexus in COVID-19. Viruses 13, 90 (2021).","journal-title":"Viruses"},{"key":"93857_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.biochi.2020.11.007","volume":"179","author":"V Rioux","year":"2020","unstructured":"Rioux, V. & Record, M. Special Section Involvement of lipids in the occurrence of COVID-19. Biochimie 179, 228 (2020).","journal-title":"Biochimie"},{"key":"93857_CR49","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI Van Der Made","year":"2020","unstructured":"Van Der Made, C. I. et al. Presence of genetic variants among young men with severe COVID-19. JAMA 324, 663\u2013673 (2020).","journal-title":"JAMA"},{"key":"93857_CR50","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 397, 952\u2013954 (2021).","journal-title":"Lancet"},{"key":"93857_CR51","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s40618-020-01307-4","volume":"43","author":"E Cure","year":"2020","unstructured":"Cure, E. & Cumhur Cure, M. COVID-19 may affect the endocrine pancreas by activating Na+\/H+ exchanger 2 and increasing lactate levels. J. Endocrinol. Investig. 43, 1167\u20131168 (2020).","journal-title":"J. Endocrinol. Investig."},{"key":"93857_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-1261-1","volume":"21","author":"M-Y Wu","year":"2020","unstructured":"Wu, M.-Y. et al. Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia. Respir. Res. 21, 1\u20136 (2020).","journal-title":"Respir. Res."},{"key":"93857_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jss.2017.06.042","volume":"219","author":"TC Rice","year":"2017","unstructured":"Rice, T. C. et al. Sphingosine rescues aged mice from pulmonary pseudomonas infection. J. Surg. Res. 219, 354\u2013359 (2017).","journal-title":"J. Surg. Res."},{"key":"93857_CR54","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.33594\/000000194","volume":"53","author":"H Carstens","year":"2019","unstructured":"Carstens, H. et al. Clinical development of sphingosine as anti-bacterial drug: Inhalation of sphingosine in mini pigs has no adverse side effects. Cell. Physiol. Biochem. 53, 1015\u20131028 (2019).","journal-title":"Cell. Physiol. Biochem."},{"key":"93857_CR55","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1159\/000445567","volume":"38","author":"ST Tabazavareh","year":"2016","unstructured":"Tabazavareh, S. T. et al. Lack of sphingosine causes susceptibility to pulmonary Staphylococcus aureus infections in cystic fibrosis. Cell. Physiol. Biochem. 38, 2094\u20132102 (2016).","journal-title":"Cell. Physiol. Biochem."},{"key":"93857_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013424","volume":"13","author":"G Marfia","year":"2021","unstructured":"Marfia, G. et al. Decreased serum level of sphingosine-1-phosphate: A novel predictor of clinical severity in COVID-19. EMBO Mol. Med. 13, e13424 (2021).","journal-title":"EMBO Mol. Med."},{"key":"93857_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03527-9","volume":"12","author":"R Nardacci","year":"2021","unstructured":"Nardacci, R. et al. Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis. Cell Death Dis. 12, 1\u201312 (2021).","journal-title":"Cell Death Dis."},{"key":"93857_CR58","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.dsx.2021.04.011","volume":"15","author":"BM Henry","year":"2021","unstructured":"Henry, B. M. et al. Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): A study from Cincinnati, USA. Diabetes Metab. Syndr. 15, 863\u2013868 (2021).","journal-title":"Diabetes Metab. Syndr."},{"key":"93857_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102489","author":"CJ Dwyer","year":"2021","unstructured":"Dwyer, C. J. et al. Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. Iscience https:\/\/doi.org\/10.1016\/j.isci.2021.102489 (2021).","journal-title":"Iscience"},{"key":"93857_CR60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/978-1-4419-6741-1_3","volume":"688","author":"J Bielawski","year":"2010","unstructured":"Bielawski, J. et al. Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS\/MS). Adv. Exp. Med. Biol. 688, 46\u201359. https:\/\/doi.org\/10.1007\/978-1-4419-6741-1_3 (2010).","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93857-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:19:03Z","timestamp":1670066343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-93857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["93857"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-93857-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14232"}}